## Abstract As the treatments of cancer progress, a certain number of cancers are curable if diagnosed early. In population‐based cancer survival studies, cure is said to occur when mortality rate of the cancer patients returns to the same level as that expected for the general cancer‐free populati
Spatial smoothing of cancer survival: a Bayesian approach
✍ Scribed by Kåre Osnes; Odd O. Aalen
- Publisher
- John Wiley and Sons
- Year
- 1999
- Tongue
- English
- Weight
- 449 KB
- Volume
- 18
- Category
- Article
- ISSN
- 0277-6715
No coin nor oath required. For personal study only.
✦ Synopsis
A major aim of this paper is to propose and evaluate a method for describing the geographical variation in cancer survival. A fully hierarchical Bayesian approach (FB) which incorporates spatial autocorrelation of the hazard ratios is presented. The method was tried out on data sets of breast cancer and malignant melanoma patients from a population-based cancer registry. The performance of FB was compared with an ordinary Cox proportional hazard method. For both cancers both methods localized some areas of increased and some areas of decreased cancer-speci"c survival. The estimates provided by the Cox and the FB approach resembled each other, but the FB approach gave more geographical details. In particular, the boundaries of the clusters of high or low survival provided by the FB are more realistic.
📜 SIMILAR VOLUMES
## Abstract Providing a geographical map for rates of mortality, incidence, or prevalence of various diseases is of great importance for national health authorities. The relative risks are used to uncover the rate of incidence for different diseases. In the classical approach, the relative risk is
We propose a Bayesian hierarchical model to estimate age-specific cancer incidence per year from age-specific cancer mortality. The model is based upon the empirical Bayesian approach of Liao and Brookmeyer (1995) and extends that model by consideration of the dependence on age. The incident cases p
In randomized clinical trials comparing treatment effects on diseases such as cancer, a multi-centre trial is usually conducted to accrue the required number of patients in a reasonable period of time. While we interpret the average treatment effect, it is necessary to examine the homogeneity of the